BWH

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Retrieved on: 
Freitag, Mai 3, 2024
Surgery, Genetics, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, General Health, Oncology, Radiation, Mohs, NCCN, Mohs surgery, American College, CME, ACMS, Abstract (summary), Neck, National Comprehensive Cancer Network, SCC, Patient, Metastasis, Neoplasm, Head, BWH

“In most cases, once a tumor is removed completely, the patient is in the clear.

Key Points: 
  • “In most cases, once a tumor is removed completely, the patient is in the clear.
  • This study included 417 patients who received definitive Mohs surgery to remove high-risk SCC tumors of the H&N with reported clear margins.
  • Presenting authors will be available to answer questions regarding their posters on Saturday, May 4, from 12-1 p.m. Mountain Standard Time.
  • Abstracts will also be in ACMS' CME & Abstract Book and available for online viewing via the Planstone abstract site.

MNA: Unsafe Patient Care Conditions Prompt Brigham and Women's Hospital Nurses to Picket on International Workers' Day as a Federal Mediator is Called in and Management Refuses to Negotiate a Fair Contract

Retrieved on: 
Mittwoch, April 10, 2024
Negotiation, National Nurses United, Hospital, Safety, Risk, International Workers' Day, Nursing, Workplace violence, Insurance, PACU, Violence, MGB, Cone Health Women's Hospital, Patient safety, Patient, Workforce, Brigham and Women's Hospital, MNA, Health, BWH

BOSTON, April 10, 2024 /PRNewswire/ -- The registered nurses of Brigham and Women's Hospital, represented by the Massachusetts Nurses Association (MNA), will hold an informational picket on Wednesday, May 1 as a federal mediator joins negotiations that have stretched since last summer. Nurses will advocate during the picket on International Workers' Day for a fair contract that invests in nurses and better enables them to provide safe patient care.

Key Points: 
  • Nurses will advocate during the picket on International Workers' Day for a fair contract that invests in nurses and better enables them to provide safe patient care.
  • "Our informational picket will show the public how seriously concerned almost 4,000 Brigham nurses are about MGB failing to invest in our workforce and address unsafe staffing throughout the hospital."
  • Nurses can join when they are not working or on break and will advocate for safe patient care without disrupting hospital access.
  • Nurses have delivered a petition signed by more than 3,000 nurses demanding the option to change insurance plans during annual enrollment.

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Retrieved on: 
Dienstag, März 19, 2024
Oncology, Health, Genetics, Research, Science, Biotechnology, ART, Radiation, SCC, Central Statistics Office (India), BWH, PNI, Risk, Patient, Journal, NCCN, Workflow, Dermatology, MPH, Recurrence, Metastasis, De-escalation, Medical imaging

Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.

Key Points: 
  • Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.
  • In nuanced discussions where the risks associated with ART may outweigh the benefits, the additional information provided by the DecisionDx-SCC test can assist in personalized decision-making.
  • The DecisionDx-SCC test can help radiation oncologists determine a more precise risk-benefit ratio for elective nodal radiation.
  • The panel recommended stronger consideration of elective nodal radiation for a DecisionDx-SCC Class 2B tumor, given the dramatically increased risk of nodal metastasis.

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Retrieved on: 
Donnerstag, März 7, 2024
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Neoplasm, BWH, Metastasis, Nebraska Medicine, SCC, University, ART, NCCN, Risk assessment, Patient, SCCS, Risk, Medical device

“Incorporating DecisionDx-SCC test results into the management of high-risk SCC can help ensure patients receive the best care possible by incorporating their biological risk of metastasis into the treatment plan.

Key Points: 
  • “Incorporating DecisionDx-SCC test results into the management of high-risk SCC can help ensure patients receive the best care possible by incorporating their biological risk of metastasis into the treatment plan.
  • DecisionDx-SCC also provided significant and clinically actionable risk stratification in various patient subgroups, including NCCN high and very high-risk, lower-stage BWH tumors and Medicare-eligible patients, further stratifying risk to help guide important treatment decisions for these patients.
  • These data support the use of DecisionDx-SCC test results, informed by a patient’s tumor biology, to guide personalized patient treatment decisions aligned to a patient’s risk of metastasis over three years.
  • “As such, we continue to develop evidence showing that our test adds independent prognostic value to the clinical and pathologic risk factors used for guiding risk-informed treatment plans within current guidelines.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Mittwoch, Februar 28, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Well, Neoplasm, Psoriasis, DecisionDx-UM, Investment, News, Growth, Table, Uveal melanoma, Epidemiology, SCC, Webcast, Diagnosis, Mortality, Woman, Melanoma, Cohort (statistics), Recurrence, BWH, Overalls, Radiation, Metastasis, Mycosis fungoides, GAAP, Journal, Net, Depreciation, PSO, Major depressive disorder, Randomized controlled trial, Atopic dermatitis, Adjustment, Practitioner, ART, Castle, National Comprehensive Cancer Network, Survival, MDD, Workflow, Acquisition, MF, Risk, Medicare, NCCN, Patient, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

MERCURY® FINANCIAL PARTNERS WITH BWH HOTELS TO OFFER CO-BRANDED VISA CREDIT CARD

Retrieved on: 
Donnerstag, Februar 29, 2024
Mercury, BWH, Visa, Senior, Enablement, BWR, Travel, Partnership, Nightclub

WILMINGTON, Del., Feb. 29, 2024 /PRNewswire/ -- Mercury Financial , a company dedicated to expanding financial inclusion, announced today an agreement in partnership with BWH Hotels (BWH).

Key Points: 
  • WILMINGTON, Del., Feb. 29, 2024 /PRNewswire/ -- Mercury Financial , a company dedicated to expanding financial inclusion, announced today an agreement in partnership with BWH Hotels (BWH).
  • Under this partnership, Mercury Financial will become the new exclusive credit card provider with Visa, a world leader in digital payments, as the payment network for the award-winning Best Western Rewards® (BWR®) loyalty program.
  • "We are delighted to become the exclusive co-branded credit card partner for such an esteemed global hospitality brand.
  • "With BWH and Visa, we will create a leading co-branded card program designed to enhance BWH's guest experience and bring them unparalleled value through our credit card program."

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

Retrieved on: 
Mittwoch, Januar 3, 2024
Associate, Ipsen, Hospital, Science, Partnership, Duvelisib, Biotechnology, Drug development, Research, Pathology, Acquisition, BWH, Brigham and Women's Hospital, Therapy, EZH2, Verastem Oncology, Hematology, Stony Brook University, PI3K, Kinetic, Patient, Harvard Medical School, AbbVie, Management

WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

Key Points: 
  • WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.
  • "Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM.
  • Dr. Kutok previously served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company's scientific strategy, preclinical development, and translational science.
  • "I am thrilled to join the ENSEM team at this exciting time," stated Dr. Jeff Kutok, Chief Scientific Officer at ENSEM.

BWH Hotels and Call2Recycle Bring Battery Recycling Practices to the Canadian Hospitality Sector

Retrieved on: 
Dienstag, Dezember 12, 2023
Carbon footprint, Community, Life, EPC, Collection, Recycling, BWH, Brand management, Carbon, Environment

Toronto, ON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Call2Recycle , Canada’s leading battery collection and recycling program, and BWH Hotels (BWH) , a leading global hospitality enterprise, are announcing a collaboration to implement battery recycling across the BWH network.

Key Points: 
  • Toronto, ON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Call2Recycle , Canada’s leading battery collection and recycling program, and BWH Hotels (BWH) , a leading global hospitality enterprise, are announcing a collaboration to implement battery recycling across the BWH network.
  • It is the first time a major company in the Canadian hospitality sector has integrated battery recycling on a large scale as part of their sustainability strategy.
  • To date, 47 BWH hotels in eight Canadian provinces and territories have joined the Call2Recycle battery recycling program, with more set to join in 2024.
  • “We are thrilled to join forces with Call2Recycle to introduce battery recycling across our Canadian portfolio of hotels,” said Michael Morton, Vice President Brand Management and Member Services at BWH Hotels.

BWH Hotels Scandinavia’s Revenue Center Selects FLYR for Hospitality as Preferred Revenue Management System

Retrieved on: 
Dienstag, Dezember 5, 2023
Hospitality, Forecasting, Acquisition, BWH, AI, UI, Revenue management, Revenue center, Automation, RMS

LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- FLYR, the AI-powered platform for travel technology, today announced that BWH Hotels Scandinavia , a leading global hospitality network that includes Best Western Hotels & Resorts (BWHR), Worldhotels, and Sure Hotels, has selected FLYR for Hospitality as its preferred Revenue Management System (RMS).

Key Points: 
  • LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- FLYR, the AI-powered platform for travel technology, today announced that BWH Hotels Scandinavia , a leading global hospitality network that includes Best Western Hotels & Resorts (BWHR), Worldhotels, and Sure Hotels, has selected FLYR for Hospitality as its preferred Revenue Management System (RMS).
  • This strategic decision will strengthen BWH Hotels’ centralized revenue management capabilities for its 56 properties across Scandinavia and enable it to grow at a more rapid pace.
  • “Our mission is to become the best performing chain in Scandinavia in the area of Revenue Management,” said Sivapol Pipatanangura, Director of Revenue Services at BWH Hotels Scandinavia.
  • “Helping our customers future-proof their businesses with a modern revenue management system is core to our vision,” said Jens Munch, CEO and co-founder of FLYR for Hospitality.

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Retrieved on: 
Dienstag, November 14, 2023
Mental Health, Medical Supplies, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Research, Annual general meeting, NCCN, ART, Lymph node, National Comprehensive Cancer Network, Risk, ASDS, Patient, BWH, SLN, SCC, Abstract, MPH, Diagnosis, University, Medicare, Society, Summary, GEP, Metastasis, T2A, Pharmaceutical industry, Medical imaging, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.
  • “The robust data presented at ASDS underscores the value of GEP testing across multiple skin cancer indications” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.
  • Summary: ART is recommended based on high-risk clinicopathologic features of SCC, but these criteria are wide-ranging, encompassing a broad range of patients.
  • Additionally, a DecisionDx-SCC Class 2B result was the only risk factor that successfully identified patients who would benefit from ART.